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Abstract
Background: Ipilimumab, a fully human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4, has
demonstrated an improvement in overall survival in two phase III trials of patients with advanced melanoma. The
primary objective of the current trial was to prospectively explore candidate biomarkers from the tumor
microenvironment for associations with clinical response to ipilimumab.
Methods: In this randomized, double-blind, phase II biomarker study (ClinicalTrials.gov NCT00261365), 82
pretreated or treatment-naïve patients with unresectable stage III/IV melanoma were induced with 3 or 10 mg/kg
ipilimumab every 3 weeks for 4 doses; at Week 24, patients could receive maintenance doses every 12 weeks.
Efficacy was evaluated per modified World Health Organization response criteria and safety was assessed
continuously. Candidate biomarkers were evaluated in tumor biopsies collected pretreatment and 24 to 72 hours
after the second ipilimumab dose. Polymorphisms in immune-related genes were also evaluated.
Results: Objective response rate, response patterns, and safety were consistent with previous trials of ipilimumab
in melanoma. No associations between genetic polymorphisms and clinical activity were observed.
Immunohistochemistry and histology on tumor biopsies revealed significant associations between clinical activity
and high baseline expression of FoxP3 (p = 0.014) and indoleamine 2,3-dioxygenase (p = 0.012), and between
clinical activity and increase in tumor-infiltrating lymphocytes (TILs) between baseline and 3 weeks after start of
treatment (p = 0.005). Microarray analysis of mRNA from tumor samples taken pretreatment and post-treatment
demonstrated significant increases in expression of several immune-related genes, and decreases in expression of
genes implicated in cancer and melanoma.
Conclusions: Baseline expression of immune-related tumor biomarkers and a post-treatment increase in TILs may
be positively associated with ipilimumab clinical activity. The observed pharmacodynamic changes in gene
expression warrant further analysis to determine whether treatment-emergent changes in gene expression may be
associated with clinical efficacy. Further studies are required to determine the predictive value of these and other
potential biomarkers associated with clinical response to ipilimumab.
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Historically, the prognosis for patients with stage IV
metastatic melanoma has been very poor, with a median
overall survival (OS) of 6-10 months and a 1-year survi-
val rate of ~25% [1,2]. After decades of disappointments
in the search for a melanoma therapy that could extend
OS beyond that seen for the standard of care, two phase
III randomized controlled trials demonstrated a statisti-
cally significant improvement in OS with ipilimumab in
combination with dacarbazine in treatment-naïve
patients [3] and as monotherapy in previously treated
patients [4] with advanced melanoma. Ipilimumab is a
fully human, monoclonal antibody that blocks cytotoxic
T-lymphocyte antigen-4 (CTLA-4) [5,6], a molecule that
down-regulates pathways of T-cell activation [7]. By
blocking CTLA-4, ipilimumab potentiates an antitumor
immune response [8-10].
Unlike conventional cancer therapies, the antitumor
responses with ipilimumab may follow an initial period
of apparent disease progression [11]. Ipilimumab therapy
is associated with mechanism-based, immune-related
adverse events (irAEs) that are inflammatory in nature
[12], most of which are reversible using treatment
guidelines provided in the US prescribing information
[13]. However, treatment-related irAEs can be severe
and, in rare instances, can be life-threatening [12].
Therefore, the ability to differentiate responders from
nonresponders prior to initiation of therapy would help
to maximize benefits associated with ipilimumab and
minimize potential risks.
Biomarkers, intrinsic patient or tumor characteristics
associated with clinical activity and/or toxicity of a given
therapy, are increasingly demonstrating value towards
the goals of personalized medicine. By allowing the pre-
diction of both beneficial and detrimental responses to a
given agent [14], biomarkers such as HER-2 in breast
cancer [15] and KRAS in colon cancer [16] are begin-
ning to change treatment paradigms. Promising biomar-
kers for melanoma include KIT and BRAF gene
mutations [17,18].
Biomarkers of clinical efficacy for immunotherapies to
treat melanoma are in early stages of development. A
few studies of melanoma patients treated with immu-
notherapies have demonstrated association between clin-
ical efficacy and gene expression profiles derived from
tumor tissue [19]. These gene expression signatures fea-
tured many immune-related genes, indoleamine 2,3-
dioxygenase (IDO), and FoxP3. The immunotherapies
tested in these studies include high- dose interleukin
(IL)-2, IL-12, peptide vaccines (including MAGE-A3),
and dendritic cells pulsed with peptide vaccines [19].
Due to the fact that only a small number of patients
had a response to therapy, there were few data points
on which to base conclusions regarding associations
between gene expression and efficacy. Previous studies
of anti-CTLA-4 therapy in melanoma patients have
shown an association between clinical activity and treat-
ment-emergent changes in immune cells, such as
increased absolute lymphocyte count and changes in
specific T-cell populations (e.g., increased frequency of
CD8+ cells) [20-24]. The primary objective of this
exploratory, phase II trial (CA184-004; http://www.clini-
caltrials.gov NCT00261365) was the prospective explora-
tion of candidate biomarkers of clinical response to
ipilimumab in the tumor microenvironment.
Methods
Patient population and study design
Previously treated and treatment-naïve patients with
advanced melanoma were treated intravenously with 3
or 10 mg/kg ipilimumab every 3 weeks (Q3W) × 4
induction doses. At Week 24 (W24), eligible patients
could receive ipilimumab maintenance treatment every
12 weeks (Q12W) or enter a companion study for fol-
low-up and/or extended therapy.
The study design is outlined in Figures 1 and 2 (CON-
SORT diagram). Patients were of either gender, ≥ 18
years of age, and met the following main criteria: life
expectancy ≥ 4 months; Eastern Cooperative Oncology
Group performance status of 0-1; histologic or cytologic
diagnosis of stage IV or unresectable stage III malignant
melanoma; and measurable lesions. Pregnant women
and individuals with ocular melanoma, serious autoim-
mune diseases, untreated active central nervous system
(CNS) metastasis, and concomitant treatment with any
anticancer or immunosuppressive agent were excluded.
The study was conducted in accordance with the
Declaration of Helsinki, the International Conference on
Harmonization Good Clinical Practice, the European
Union Directive 2001/20/EC, and the United States
Code of Federal Regulations 21CFR50. The protocol and
patient-informed consent form received approval by
Institutional Review Boards or Independent Ethics Com-
mittees. Written informed consent was obtained for all
patients.
Measurements of clinical efficacy
Investigator assessment of best overall response (BOR),
determined between the date of first ipilimumab dose
and the last tumor assessment (TA), was image-based
and scored using modified World Health Organization
criteria [25]. Patients who underwent excision or resec-
tion of any index lesions or received anticancer thera-
pies other than ipilimumab were excluded from
response evaluations.
For BOR, complete response (CR) required confirma-
tion by a repeat, consecutive TA no less than 4 weeks
after the criteria were first met; partial response (PR)
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repeat assessment; and stable disease (SD) included
those who met criteria for SD at Week 12 and those
with unconfirmed CR or PR. Efficacy endpoints included
B O Rr a t e( B O R R )( t o t a lp a t i e n t sw i t hC Ro rP Rd i v i d e d
by total treated patients); disease control rate (DCR)
(total patients with BOR of CR, PR, or SD divided by
total treated patients); progression-free survival (PFS);
OS; survival rate; response duration; proportion of
patients with response duration ≥ 24 weeks; and time to
response.
For the purpose of biomarker analyses, clinical activity
was defined as a three-level categorical variable derived
from BOR, with levels Benefit, Non-Benefit, and
Unknown. The Benefit group included patients with BOR
of CR, PR, or SD lasting ≥ 24 weeks from first ipilimumab
dose. The Non-benefit group included patients with BOR
of PD or SD ending prior to 24 weeks from first ipilimu-
mab dose. The Unknown group included patients with
unknown BOR, or BOR of SD with duration censored
before 24 weeks from date of first dose and a death date
either missing or at least 24 weeks from date of first dose.
Safety assessments
Adverse events (AEs) were recorded based on MedDRA
v10.0 system organ class (SOC) and Preferred Terms
(PT) and listed by total AEs, serious AEs, AEs leading to
ipilimumab discontinuation, and irAEs. Deaths within 70
days (5 ipilimumab half-lives) after last dose and cause
of death were recorded. On-study and serious irAEs
were summarized by SOC, PT, and worst grade, and
analyzed for 5 subcategories: gastrointestinal, liver, skin,
endocrine, and other.
Biomarker assays
Tumor biopsies were performed prior to ipilimumab
treatment and 24 to 72 hours after the second dose
(W4). Fresh tumor biopsies were evaluated by a central,
independent pathologist. Biopsies were evaluated by
immunohistochemistry (IHC) for the candidate biomar-
kers FoxP3, granzyme B, perforin, CD4, CD8, CD45RO,
and IDO; antibodies and conditions used for each analy-
sis are detailed in Table S1 (Additional File 1). Four-
micron serial sections of formalin-fixed, paraffin-
embedded tissue blocks were mounted on glass micro-
scope slides and dewaxed with four 5-minute changes of
xylenes followed by a graded alcohol series to distilled
water. Steam heat-induced epitope recovery (SHIER)
was used with appropriate SHIER solution for 20 min-
utes in the capillary gap of the upper chamber of a
Black and Decker
® Steamer [26]. Proteinase K digestion
with and without SHIER pretreatment was also used.
Slides were permanently cover-slipped with glass and
CytoSeal and staining was assessed under a microscope.
Screening Induction Maintenance Follow-up
Ipilimumab
10 mg/kg (n=42)
Q3W x4
Ipilimumab
3 mg/kg (n=40)
Q3W x4
Ipilimumab
10 mg/kg
Q12W
Ipilimumab
3 mg/kg
Q12W
Advanced
melanoma
N = 82
Treatment naïve
(n = 20)
Previously-treated
(n = 62)
W1 W4 W7 W10 W12 W24 W36 W48+
Ipilimumab
Dosing
Tumor
Biopsy
Influ/pneumo
vaccine booster
Viral/bacterial
antibody titers
†
*
+
Figure 1 Dosing and testing schedule: CA184-004. *Tumor biopsy was performed at baseline and 24 to 72 hours after the second dose of
ipilimumab.
†Influenza/pneumococcal booster administered 5 days after first dose of ipilimumab. Q3W: every 3 weeks; Q12W: every 12 weeks.
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0.5 for 9 levels) using methods detailed in Table S2 (Addi-
tional File 2). Tumor characteristics (normal tissue, viable
tumor, necrotic tumor, fibrotic regression, tumor-infiltrat-
ing lymphocytes [TILs], and peritumoral immune cells)
were assessed by hematoxylin and eosin (H&E) staining;
results were scored as 0%, ≤ 50%, or > 50% staining, also
detailed in Table S2 (Additional File 2). TIL and peritu-
moral immune cell scores were based on percentage of the
tumor; scores for the other characteristics were based on
percentage of the entire specimen. IHC and H&E analyses
were performed by an independent laboratory blinded to
response status and timing of biopsy.
Gene expression profiling using microarrays
Tumor biopsy messenger ribonucleic acid (mRNA)
expression profiles were assessed using the HG-
U133A_2 HT GeneChip™ microarray system (Affyme-
trix, Santa Clara, CA). Briefly, total RNA was extracted
from fresh tissue samples using the Prism 6100 (Applied
Biosystems, Foster City, CA), purified by RNAClean Kit
(Agencourt Bioscience Corporation; Beverly, MA), and
evaluated on a 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA). Complementary DNA preparation and
hybridization on HT-HG-U133A 96-array plates fol-
lowed manufacturer’s protocols (Affymetrix, Santa Clara,
CA). Appropriate Affymetrix control probe sets were
examined to ensure quality control for the cDNA synth-
esis and the hybridization step.
Genetic polymorphisms
Associations between genetic polymorphisms and clini-
cal activity were investigated by genotyping peripheral
blood for 20 single nucleotide polymorphisms (SNPs)
and two deletions in 10 immune-related genes (BTNL2,
CCR5, CD86, CTLA-4, IFNAR1, IFNAR2, IFNG, IL23R,
NOD2, and PTPN22). The presence of allele *0201 at
locus HLA-A and medium-resolution HLA-A and HLA-
B genotypes were also assessed.
Data analyses and statistical methodology
Efficacy analyses were based on all randomized patients
or subsets of patients defined by baseline characteristics.
BORR and frequencies of BOR values were calculated
ICF Signed
Screening/Baseline
Randomized to Study,
if eligible
Induction Period
TA; Ipilimumab at W1, W4, W7, W10
No PD between W12 and W24
PD on
or
after W12
Maintenance Period
Toxicity requiring
ipilimumab discontinuation
yes no
TA
only
TA; ipilimumab
Q12 weeks
Follow-up Period
or
Entry to CA184-025, if eligible
Day –28
to
Day –1
Baseline
Day 1
W12*, W16,
W20, W24
W1
to
W24
Q6 weeks to
W48 then Q12
weeks
W24
to
W48
None
or per CA184-025
as applicable
TA Timeline
Figure 2 CONSORT diagram: study CA184-004. *Mandatory TA. CONSORT: Consolidated Standards of Reporting Trials; ICF: informed consent
form; PD: progressive disease; TA: tumor assessment; W: study week.
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vals (CIs) for within-dose-group BORR were calculated
using the method of Clopper and Pearson [27]. Time to
response in patients with BOR of CR or PR was summar-
ized using descriptive statistics (median, minimum, maxi-
mum). PFS and OS within dose groups was estimated
using the Kaplan-Meier product-limit method and
included medians and corresponding 2-sided 95% CIs
calculated using the method of Brookmeyer and Crowley
[28]. One-year survival rate was calculated using the
Kaplan-Meier product-limit method and reported with
corresponding 2-sided 95% bootstrap CIs.
Response-evaluable patients in both dose groups were
combined for biomarker analyses to increase the power to
detect associations. Unless otherwise noted, all biomarker
analyses were performed with S-PLUS 7.0.6 [29]. Using
logistic regression of clinical activity on a biomarker,
ignoring dose group, a 2-tailed likelihood-ratio test (LRT)
of association with 80 patients and significance level of
0.05 has 90% power to detect an odds ratio (OR) of 2.24
(odds of activity when the biomarker is at its mean over
that when it is 1 standard deviation from the mean).
Linear logistic regression was used to model the prob-
ability of clinical activity as an additive function of ipili-
mumab dose and pretreatment value of an IHC or H&E
measure. IHC measures were used as continuous-valued
predictors. H&E measures were used as binary predic-
tors (positive score or not). P-values are from a logistic
regression LRT of whether the effect of an IHC or H&E
measure on probability of clinical activity is null. Linear
logistic regression was used to model the probability of
clinical activity as an additive function of ipilimumab
dose and change from baseline of an IHC or H&E mea-
sure. P-values are from a logistic regression LRT of
whether the effect of change from baseline is null.
Gene expression data were normalized using the
Robust Multichip Average method [30] and the resulting
log2-transformed expression levels were used for subse-
quent analyses. For each probe set, effects of time and
ipilimumab dose on expression level were evaluated by
fitting a linear mixed effects model with time, dose, and
time-by-dose interactions as fixed effects and individual-
patient overall mean expression level as random inter-
cept. The fixed effects structure allows the model to
estimate four different mean expression values, one at
each time point in each dose group. The random inter-
cept allows the model to account for a possible correla-
tion between the pre- and post-treatment expression
levels within each subject. Probe sets wherein expression
changed over time were selected using a two-degrees-of-
freedom F-test of the null hypothesis that there is no
mean change from baseline (pretreatment) for either
dose group. Probe sets wherein mean expression dif-
fered between dose groups were selected using a similar
F-test of the null hypothesis that there is no difference
in mean expression between dose groups for either time
point. A false discovery rate (q-value) approach [31] was
used to adjust for multiple testing. Analyses were per-
formed using S-PLUS v7.0.6 for Linux, Bioconductor
v1.14.0 (Affy package) [32] and q-value package v1.10.0
[29] for R v2.5.0 [33].
Pharmacodynamic analysis of gene expression was
b a s e do nd a t af r o ma l lt r e a t e dp a t i e n t sw i t ha n ys u c h
data; it was not limited to patients who had both pre-
treatment and post-treatment evaluable biopsies. Sixteen
(16) patients had only pretreatment gene expression
data. In theory, inclusion of these 16 patients may have
introduced bias due to informative missingness. This
bias is likely to be small, however, because (1) using a
linear mixed effects model can reduce such bias; and (2)
the clinical outcomes for the 16 patients having only
pretreatment microarray data were similar to those for
t h e5 4p a t i e n t sw i t hb o t hp r e -a n dp o s t - t r e a t m e n t
microarray data (12.5% vs 11.0% CR or PR; 12.5% vs.
18.5% SD; and 75.0% vs. 70.5% PD or UN, respectively).
An obvious alternative approach, complete-case analysis,
would be subject to its own biases in the presence of
informative missingness, whilst also suffering from
reduced precision.
Exact tests of Hardy-Weinberg equilibrium were per-
formed for gene polymorphisms, and logistic regression
was used to model the probability of clinical activity as
a function of genotype.
Results
Fourteen sites in seven European, North American, and
South American countries enrolled 101 patients; of
these, one patient withdrew consent and 18 who no
longer met study criteria were not randomized (12 due
to CNS metastasis or active CNS disease, one due to
stomach hemorrhage, one had no measurable disease,
and four did not meet other inclusion/exclusion cri-
teria). The remaining 82 patients were randomized
between January 2006 and May 2007 to receive ipilimu-
mab 3 mg/kg (n = 40) or 10 mg/kg (n = 42). Baseline
characteristics of randomized patients (Table 1) were
generally consistent between dose groups.
Clinical efficacy
There were no meaningful differences in clinical activity
between the two ipilimumab doses (Table 2). During the
study, patterns of tumor shrinkage after PD or mixed
shrinkage and progression were consistent with those
seen in other ipilimumab melanoma trials [34-36]. Two
patients with BOR of PD were followed beyond PD
without administration of other anticancer treatments;
one patient in the 10 mg/kg group had subsequent
shrinkage and disappearance of lesions and one patient
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and shrinkage of others. Across groups, ongoing
responses were observed in 7 of 8 responders at data-
base lock. Due to the small number of patients in each
dose group with BOR of CR, PR, or SD, only one of
whom progressed on study (results not shown), results
were inconclusive for response duration and disease
control, major durable response rate (proportion of
patients with CR or PR lasting ≥ 24 weeks), and major
durable disease control rate (proportion of patients with
CR, PR, or SD lasting ≥ 24 weeks). Forty-five percent of
patients in the 3 mg/kg group and 47.6% in the 10 mg/
k gg r o u pd i e do n - s t u d y ;m e d i a nf o l l o w - u pw a s8 . 9
months and 8.6 months, respectively.
Safety
Safety results are summarized in Table 3. The incidence
of irAEs was similar between dose groups; however,
irAEs were generally less severe with the lower dose.
Two drug-related deaths due to large intestine perfora-
tion were reported: one in the 3 mg/kg group within 70
days of last ipilimumab dose and one in the 10 mg/kg
group more than 70 days after last ipilimumab dose.
Biomarker Evaluation - Primary Objective
To assess potential associations between clinical activity
and putative biomarkers, patients were classified into
three groups based on BOR (see Methods subsection
Measurements of clinical efficacy). The Benefit group
Table 1 Baseline characteristics - randomized patients
Characteristic Ipilimumab 3 mg/kg (n = 40) Ipilimumab 10 mg/kg (n = 42) Total (N = 82)
Male gender, % 70.0 57.1 63.4
Race, n (%)
Asian 1 (2.5) 0 1 (1.2)
Black 0 1 (2.4) 1 (1.2)
White 39 (97.5) 41 (97.6) 80 (97.6)
Age in yrs, mean (range) 53.9 (23.0-78.0) 56.2 (26.0-87.0) 55.0 (23.0-87.0)
< 65, n (%) 31 (77.5) 29 (69.0) 60 (73.2)
≥ 65, n (%) 9 (22.5) 13 (31.0) 22 (26.8)
Disease stage, n (%)
III 1 (2.5) 2 (4.8) 3 (3.7)
IV 39 (97.5) 40 (95.2) 79 (96.3)
M-stage, n (%)
M0 0 2 (4.8) 2 (2.4)
M1A 12 (30.0) 9 (21.4) 21 (25.6)
M1B 6 (15.0) 3 (7.1) 9 (11.0)
M1C 22 (55.0) 28 (66.7) 50 (61.0)
ECOG-PS, n (%)
0 25 (62.5) 27 (64.3) 52 (63.4)
1 15 (37.5) 15 (35.7) 30 (36.6)
Time since initial diagnosis in months, mean (range) 69.0 (1.1-384.0) 55.8 (3.8-237.9) 62.2 (1.1-384.0)
Any prior systemic therapy received, n (%) 29 (72.5) 33 (78.6) 62 (75.6)
Number received
1, n (%) 15 (37.5) 19 (45.2) 34 (41.5)
2, n (%) 7 (17.5) 8 (19.0) 15 (18.3)
3, n (%) 6 (15.0) 5 (11.9) 11 (13.4)
≥ 5, n (%) 1 (2.5) 1 (2.4) 2 (2.4)
Any prior immunotherapy received, n (%) (57.5) (61.9)
interleukin-2, n (%) (45.0) (38.1)
interferon-a, n (%) (22.5) (19.0)
Setting of prior therapy*
Adjuvant therapy, n (%) 10 (25.0) 10 (23.8) 20 (24.4)
Metastatic disease, n (%) 26 (65.0) 28 (66.7) 54 (65.9)
Neoadjuvant therapy, n (%) 0 1 (2.4) 1 (1.2)
*Systemic therapy may have been received in > 1 setting.
ECOG-PS: Eastern Cooperative Oncology Group performance status.
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24 weeks from first ipilimumab dose. Of the 82 patients
treated in CA184-004, 12 patients (14.6%) were in the
Benefit Group, 50 (61.0%) were in the Non-benefit
Group, and 20 (24.4%) were in the Unknown category.
Ninety-one tumor biopsies (50 pretreatment, 41 post-
treatment) from 57 patients were sectioned and stained
using hematoxylin and eosin (H&E) to visualize tumor
infiltrating lymphocytes (TILs) (Figure 3A, B), or using
immunohistochemistry (IHC) to evaluate other biomar-
kers (Figure 3C-F). The number of samples evaluable
varied among individual biomarkers examined, as indi-
cated in the tables summarizing these results. To
increase the power of the study, biomarker results from
both dose groups were pooled.
H&E-stained sections were scored to quantify the pre-
valence of TILs (Additional File 2 Table S2). Although
there was not convincing evidence that baseline TIL
scores were associated with clinical activity, a statisti-
c a l l ys i g n i f i c a n t( p=. 0 0 5 )a ssociation was observed
between change from baseline in TILs and clinical activ-
ity (Table 4, Additional File 3 Table S3, Figure 3A and
3B). In the Benefit group, 57.1% of patients had a post-
treatment increase in TILs and none had a decrease. In
contrast, 10.0% of Non-benefit group patients had an
increase in TILs relative to baseline and 15.0% had a
decrease. The estimated OR of 13.27 indicates that the
odds of benefit increased approximately 13-fold for each
one-unit increase from baseline in TIL score.
Figure 3 shows examples of FoxP3 (C, D) and IDO (E,
F) immunostaining. At baseline, FoxP3 staining was
apparent in the nuclei of mononuclear leukocytes, and
was more prominent in samples from patients that later
derived clinical benefit from ipilimumab treatment (D)
than in samples from the Non-benefit group (C). Like-
wise, pretreatment samples showed stronger IDO stain-
ing for patients that later derived clinical benefit from
treatment (F) than those who did not (E).
IHC-stained sections were scored (as described in
Additional File 2 Table S2) to facilitate statistical analy-
sis of the trends observed. Statistically significant asso-
ciations were observed between clinical activity and
pretreatment FoxP3 and IDO expression (p = 0.014 and
0.012, respectively) (Table 4, Additional Files 4 and 5
Tables S4 and S5). FoxP3 was detected in 75.0% of eva-
luable pretreatment biopsies in the Benefit group and
36.0% in the Non-benefit group. IDO was detected in
37.5% of evaluable pretreatment biopsies in the Benefit
group and 11.1% in the Non-benefit group. Estimated
ORs for FoxP3 and IDO were 10.38 and 8.72, respec-
tively, indicating that the odds of benefit increased
approximately 10- and 9-fold, respectively, for each one-
unit increase in pretreatment score. No associations
were apparent between clinical activity and total infil-
trate; expression of CD4, CD45RO, CD8, granzyme B,
or perforin; or amount of normal tissue, viable tumor,
necrotic tumor, fibrotic regression, or peritumoral
immune cells.
Pharmacodynamic effects on gene expression
mRNA expression profiles were measured in 70 pre-
treatment (baseline) and 58 post-treatment (W4) fresh
tumor biopsy samples (one replicate per sample); 54
represented matched pairs from the same patient.
Table 2 Efficacy summary
Efficacy Measure Ipilimumab 3 mg/kg (n = 40)* Ipilimumab 10 mg/kg (n = 42)*
Response, n (%)
CR 0 1 (2.4)
PR 3 (7.5) 4 (9.5)
SD 10 (25.0) 3 (7.1)
PD 19 (47.5) 24 (57.1)
Unknown 8 (20.0) 10 (23.8)
BORR, % (95% CI) 7.5 (1.6, 20.4) 11.9 (4.0, 25.6)
DCR, % 32.5 19.0
OS, median, in months 12.9 11.8
1-year survival rate
†, % (95% CI) 60.9 (41.7, 74.9) 44.2 (24.1, 64.1)
PFS, median (95% CI), in months 2.63 (2.56, 3.88) 2.56 (2.50, 2.66)
Progressed or died, n (%) 28 (70.0) 32 (76.2)
Time to response, median (min- max), in months 2.5 (2.1-5.3) 2.6 (2.6-3.6)
*Four patients (10.0%) in the 3 mg/kg group and five (11.9%) in the 10 mg/kg group were censored from the analyses of response-based endpoints (BORR, PFS,
DCR, time to response) because of excision or resection of index lesions.
†Estimated.
BORR: best overall response rate; CI: confidence interval; CR: complete response; DCR: disease control rate; OS: overall survival; PD: progressive disease; PFS:
progression-free survival; PR: partial response; SD: stable disease.
Hamid et al. Journal of Translational Medicine 2011, 9:204
http://www.translational-medicine.com/content/9/1/204
Page 7 of 16Although not reported, reasons for lack of evaluable
biopsy may include poor sampling technique or insuffi-
cient tissue. Of 22,215 initial probe sets, 17,519 with
maximum log2 expression level > 4 and coefficient of
variation > 5% across all samples were analyzed further.
These filters remove probe sets with very low expression
levels in all samples or with very little variability across
all samples, respectively. They were applied because
unexpressed probe sets or probe sets with nearly con-
stant expression were not of interest. After correcting
for multiple testing, 466 probe sets demonstrated signifi-
cant (q-value < 0.05) changes from baseline (Additional
File 6 Figure S1): 286 had estimated increases in expres-
sion from baseline for both the 3 and 10 mg/kg dose
groups (Additional File 7 Table S6); 165 had estimated
decreases in expression from baseline for both dose
groups (Additional File 8 Table S7); and 15 had an
opposite direction of estimated change from baseline for
the two dose groups (Additional File 9 Table S8).
Significant increases in post-treatment expression
from baseline were seen for various immune-response
genes (immunoglobulins, granzyme B, perforin-1, granu-
lysin, CD8 b-subunit, and T-cell receptor-a and -b sub-
units). Genes with significantly decreased expression
from baseline included at least one known melanoma
antigen: tyrosinase-related p r o t e i n - 2( D C T ) .O fa l lt h e
genes tested, DCT had the strongest negative time effect
at 3 mg/kg, followed by solute carrier family 45, mem-
ber 2 (a protein that is present in a high percentage of
melanoma cell lines), G protein-coupled receptor 143,
Table 3 Safety summary
Event Ipilimumab 3 mg/kg (n = 40) Ipilimumab 10 mg/kg (n = 42)
Death, n (%)
All 18 (45.0) 20 (47.6)
Within 70 days of last dose 8 (20.0) 8 (19.0)
Within 30 days of last dose 3 (7.5) 4 (9.5)
Serious AE, n (%)
All 18 (45.0) 20 (47.6)
Drug-related 7 (17.5) 8 (19.0)
AE leading to study discontinuation, n (%) 5 (12.5) 11 (26.2)
Drug-related AE, n (%)
Any grade 33 (82.5) 32 (76.2)
Grade 3-4 6 (15.0) 13 (31.0)
Grade 5 1 (2.5) 1 (2.4)
irAE, n (%)
Overall
Any grade 22 (55.0) 28 (66.7)
Grade 3-4 3 (7.5) 8 (19.0)
Grade 5 1 (2.5) 1 (2.4)
GI
Any grade 11 (27.5) 19 (45.2)
Grade 3-4 3 (7.5) 3 (7.2)
Grade 5 1 (2.5) 1 (2.4)
Liver
Any grade 0 2 (4.8)
Grade 3-4 0 2 (4.8)
Endocrine
Any grade 2 (5.0) 2 (4.8)
Grade 3-4 0 2 (4.8)
Skin
Any grade 16 (40.0) 21 (50.0)
Grade 3-4 0 1 (2.4)
Other
Any grade 1 (2.5) 3 (7.1)
Grade 3-4 0 1 (2.4)
AE: adverse event; GI: gastrointestinal; irAE: immune-related adverse event.
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Page 8 of 16and carbonic anyhydrase XIV. After multiplicity correc-
tion, no probe sets met the q-value threshold of < 0.05
for significant dose effect or demonstrated a significant
difference between dosage groups in mean change in
expression from baseline using a one-degree-of-freedom
F-test of the time-by-dose interaction.
Genetic polymorphisms did not predict clinical activity
Allele and genotype frequencies for 22 genetic polymorph-
isms in peripheral blood were summarized for all
response-evaluable patients (Table 5). Of the 22 poly-
morphisms, 20 were SNPs and 2 (NOD2 rs5743293 and
CCR5 CCR5d32 [rs333]) were deletions; the term SNPs
IDO  FoxP3 
D 
A  Baseline   
F 
H&E 
B  Post-treatment   F  Benefit group 
E  Non-Benefit group   
D  Benefit group 
C  Non-Benefit group   
* 
Figure 3 Tumor tissue samples from patients with malignant melanoma treated with ipilimumab.6 0 ×i m a g e so fs k i n( A ,B ,F ,S u b j e c t
04055; E, Subject 04024) and soft tissue (C, Subject 04066; D, Subject 04002) involved with metastasis and infiltration of melanoma cells,
respectively. (A-B) Skin under the epidermis stained with hematoxylin and eosin (H&E) before (A) and after (B) treatment with ipilimumab.
Melanoma cells are characterized by abundant cytoplasm, large and central nuclei, apparent nucleolus (large arrows). In contrast, melanin
pigment (star) is associated with mononuclear leukocytes (small arrows). Note the increase in tumor-infiltrating mononuclear leukocytes (TILs)
post-treatment (B) relative to the baseline (A) in this clinical benefit subject. (C-D) FoxP3 positive staining (with anti-FOXP3) of the nuclei of
mononuclear leukocytes (small arrows) in a clinical benefit subject at baseline (D). Non-clinical benefit subject (C) shows no staining of
mononuclear leukocytes at baseline. (E-F) IDO expression (anti-IDO staining) at baseline in a clinical benefit subject (F) shows staining of
mononuclear leukocytes (small arrows), and spindloid and endothelial cells (large arrows). IDO expression is minimal in the non-clinical benefit
subject (E) at baseline, showing focal and weak staining of melanoma cells (red arrow). H&E scores for tumor-associated infiltrating mononuclear
leukocytes: (A) ≤ 50%, (B) > 50%. Staining scores for FoxP3: (C) 0, (D) 1. Staining scores for IDO: (E) 0, (F) 1.
Table 4 Association of clinical activity with tumor biomarkers
Biomarker Observed Effect P-value*
Benefit Group
(n = 21)
Non-benefit Group
(n = 43)
TILs change from baseline to week 4, by H&E 4/7 increase
0/7 decrease
3/7 no change
2/20 increase
3/20 decrease
15/20 no change
0.005
FoxP3 expression at baseline, by IHC 6/8 evaluable patients positive 9/25 evaluable patients positive 0.014
IDO expression at baseline, by IHC 3/8 evaluable patients positive 3/27 evaluable patients positive 0.012
*P-values are for tests of association between biomarker and clinical activity and are uncorrected for multiple testing.
H&E: hematoxylin and eosin; IDO: indoleamine 2,3-dioxygenase; IHC: immunohistochemistry; TILs: tumor-infiltrating lymphocytes.
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type score for at least one SNP was available for 76 treated
patients of whom 65 were response evaluable. All but two
patients with SNP data were Caucasian, so analyses were
not stratified by race. No SNPs were monomorphic in this
sample of patients. No statistically significant departures
from Hardy-Weinberg equilibrium were observed. For
SNPs rs2066844, rs2066845, and rs5743293 in gene
NOD2, only 2 to 4 patients possessed a minor allele.
Because of such limited polymorphism, these SNPs were
excluded from further analyses. For the remaining 19
SNPs, no statistically significant associations with clinical
activity were observed (Table 6); however, there was lim-
ited power to detect such associations given the relatively
small number of patients with SNP data.
Presence or absence of allele HLA-A*0201 could be
determined for 67 of the 71 response-evaluable patients.
Medium-resolution HLA genotypes also could be
obtained for 67 of these patients, but presence/absence
status of the five HLA alleles present in at least 10% of
patients could not be determined for 5 to 15 of these
patients. Presence of allele *0201 at locus HLA-A was
cross-tabulated by clinical activity status (Table 7). No
association between presence of this allele and clinical
activity was apparent. Similarly, presence of the five
common HLA-A alleles was cross-tabulated by clinical
activity status (Table 8) and no associations were
apparent.
Discussion
Clinical activity and safety results from the present study
are similar to those of other clinical trials of ipilimumab
in advanced melanoma. In this study, BORRs of 7.5%
and 11.9% and DCRs of 32.5% and 19% were observed
Table 5 Allele and genotype distributions for 22 genetic polymorphisms: all response-evaluable patients with
genotype data
Gene Poly-
morphism
Major
Allele (1)
Minor
Allele (2)
HWE
P-
value
Minor Allele
Frequency (%)
Number of Patients (%)
Genotype
11
Genotype
12
Genotype
22
Genotype
Unknown
Total
BTNL2 rs2076530 A G 0.31 41.4 24 (37.5) 27 (42.2) 13 (20.3) 1 (1.5) 65 (85.5)
CCR5 CCR5d32 wt d32 0.49 10.0 53 (81.5) 11 (16.9) 1 (1.5) 0 (0.0) 65 (85.5)
CCR5 rs1799987 A G 0.30 39.2 26 (40.0) 27 (41.5) 12 (18.5) 0 (0.0) 65 (85.5)
CD86 rs1129055 G A 0.15 31.5 33 (50.8) 23 (35.4) 9 (13.8) 0 (0.0) 65 (85.5)
CD86 rs2681417 A G 1.00 2.4 60 (95.2) 3 (4.8) 0 (0.0) 2 (3.1) 65 (85.5)
CTLA4 rs11571317 C T 1.00 4.6 59 (90.8) 6 (9.2) 0 (0.0) 0 (0.0) 65 (85.5)
CTLA4 rs1863800 C T 0.79 37.3 24 (38.1) 31 (49.2) 8 (12.7) 2 (3.1) 65 (85.5)
CTLA4 rs231775 A G 0.19 39.8 26 (40.6) 25 (39.1) 13 (20.3) 1 (1.5) 65 (85.5)
CTLA4 rs3087243 G A 1.00 36.5 25 (39.7) 30 (47.6) 8 (12.7) 2 (3.1) 65 (85.5)
CTLA4 rs4553808 A G 0.30 23.4 39 (60.9) 20 (31.2) 5 (7.8) 1 (1.5) 65 (85.5)
IFNAR1 rs2257167 G C 0.75 26.2 36 (55.4) 24 (36.9) 5 (7.7) 0 (0.0) 65 (85.5)
IFNAR2 rs7279064 T G 0.01 34.6 23 (35.4) 39 (60.0) 3 (4.6) 0 (0.0) 65 (85.5)
IFNG rs2069705 T C 0.58 34.6 29 (44.6) 27 (41.5) 9 (13.8) 0 (0.0) 65 (85.5)
IFNG rs2430561 A T 0.80 46.9 17 (26.6) 34 (53.1) 13 (20.3) 1 (1.5) 65 (85.5)
IL23R rs1004819 C T 0.44 38.5 26 (40.0) 28 (43.1) 11 (16.9) 0 (0.0) 65 (85.5)
IL23R rs11209026 G A 1.00 7.7 55 (84.6) 10 (15.4) 0 (0.0) 0 (0.0) 65 (85.5)
IL23R rs2201841 T C 0.59 35.9 25 (39.1) 32 (50.0) 7 (10.9) 1 (1.5) 65 (85.5)
IL23R rs7517847 T G 0.43 39.8 25 (39.1) 27 (42.2) 12 (18.8) 1 (1.5) 65 (85.5)
NOD2 rs2066844 C T 1.00 1.5 63 (96.9) 2 (3.1) 0 (0.0) 0 (0.0) 65 (85.5)
NOD2 rs2066845 G C 1.00 1.6 62 (96.9) 2 (3.1) 0 (0.0) 1 (1.5) 65 (85.5)
NOD2 rs5743293 D I 1.00 2.3 62 (95.4) 3 (4.6) 0 (0.0) 0 (0.0) 65 (85.5)
PTPN22 rs2476601 G A 1.00 4.6 59 (90.8) 6 (9.2) 0 (0.0) 0 (0.0) 65 (85.5)
11 = major-allele homozygote; 12 = heterozygote; 22 = minor-allele homozygote.
Denominator for Minor Allele Percent is number of known alleles in row.
Denominator for percents in columns “11”, “12”, and “22” is number of patients in row who have a known genotype.
Denominator for percents in column “Genotype Unknown” is total number of patients in row.
Denominator for percents in column “Total” is total number of patients with genotype data.
rs1799987 is also known as rs28897671; rs2430561 is also known as (+ 874A- > T); CCR5d32 = rs333.
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Page 10 of 16for the 3 mg/kg and 10 mg/kg groups, respectively.
There results are comparable to BORRs of 5.8% to
15.8% and DCRs of 20% to 30% for 10 mg/kg ipilimu-
mab monotherapy in phase II studies [8-10], and to a
BORR of 10.9% and DCR of 28.5% for 3 mg/kg ipilimu-
mab monotherapy in a phase III trial [4]. The 1-year
survival rates of 60.9% and 44.2% for 3 and 10 mg/kg
ipilimumab, respectively, were also similar to those of
previous phase II studies (47.2% to 62.4% for 10 mg/kg
ipilimumab) [8-10] and to the phase III trial (45.6% for
3 mg/kg ipilimumab) [4]. Safety results from CA184-004
are consistent with those from a combined analysis of
Table 6 Prediction of clinical activity status by genotype at each of 19 genetic polymorphisms: all response-evaluable
patients with genetic polymorphism data and status = benefit or non-benefit.
Gene Polymorphism N DF P-value OR: Genotype
1/2 vs 1/1
OR: Genotype
2/2 vs 1/1
Estimate 95% CI Estimate 95% CI
BTNL2 rs2076530 56 2 0.48 0.40 0.08, 1.93 0.81 0.12, 5.25
CCR5 CCR5d32 57 2 0.54 0.41 0.04, 3.83 0.00 0.00, Inf
CCR5 rs1799987 57 2 0.80 0.76 0.17, 3.39 1.35 0.25, 7.35
CD86 rs1129055 57 2 0.11 1.92 0.50, 7.38 0.00 0.00, Inf
CD86 rs2681417 55 1 0.52 2.39 0.18, 31.0 NA NA, NA
CTLA4 rs11571317 57 1 0.78 0.73 0.07, 7.25 NA NA, NA
CTLA4 rs1863800 55 2 0.06 0.35 0.08, 1.45 0.00 0.00, Inf
CTLA4 rs231775 56 2 0.05 0.43 0.07, 2.73 3.75 0.72, 19.42
CTLA4 rs3087243 55 2 0.07 0.39 0.09, 1.62 0.00 0.00, Inf
CTLA4 rs4553808 56 2 0.08 0.19 0.02, 1.76 3.25 0.37, 28.28
IFNAR1 rs2257167 57 2 0.98 0.93 0.23, 3.80 1.24 0.10, 14.60
IFNAR2 rs7279064 57 2 0.59 0.83 0.22, 3.15 0.00 0.00, Inf
IFNG rs2069705 57 2 0.79 0.71 0.18, 2.82 0.50 0.05, 5.31
IFNG rs2430561 56 2 0.67 1.22 0.20, 7.31 2.36 0.30, 18.72
IL23R rs1004819 57 2 0.95 0.81 0.19, 3.37 0.97 0.14, 6.52
IL23R rs11209026 57 1 0.40 0.42 0.05, 3.93 NA NA, NA
IL23R rs2201841 56 2 0.82 0.64 0.15, 2.65 0.80 0.07, 9.43
IL23R rs7517847 56 2 0.35 2.33 0.50, 10.85 0.67 0.06, 7.77
PTPN22 rs2476601 57 1 0.95 0.93 0.09, 9.69 NA NA, NA
1/1 = major-allele homozygote; 1/2 = heterozygote; 2/2 = minor-allele homozygote.
CI = Confidence Interval.
DF = degrees of freedom for likelihood-ratio test (LRT).
Inf = infinite.
N = number of patients with non-missing genotypes.
OR = odds ratio comparing the odds of Status = Benefit between two genotype classes. OR > 1 means that the odds of Benefit were greater for class 1/2 or 2/2
than for class 1/1.
NA = not estimable.
P-value is for a logistic regression LRT of whether both (if > 1 estimable) odds ratios = 1.
Table 7 Presence of allele *0201 at locus HLA-A by clinical activity status: all response-evaluable patients.
Clinical Activity Status n (%)
Allele Absent Allele Present Allele Status Unknown Total
Benefit 4 (33.3) 8 (66.7) 0 (0.0) 12 (16.9)
CR or PR 3 (37.5) 5 (62.5) 0 (0.0) 8 (11.3)
Prolonged SD 1 (25.0) 3 (75.0) 0 (0.0) 4 (5.6)
Non-benefit 21 (45.7) 25 (54.3) 3 (6.1) 49 (69.0)
Unknown 6 (66.7) 3 (33.3) 1 (10.0) 10 (14.1)
Total 31 (46.3) 36 (53.7) 4 (5.6) 71 (100.0)
Denominator for percents in columns “Allele Absent” and “Allele Present” is number of patients in row who have a known allele status.
Denominator for percents in column “Allele Status Unknown” is total number of patients in row.
Denominator for percents in column “Total” is number of response-evaluable patients.
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[37]. In the 10 mg/kg arm, drug-related AEs and irAEs
occurred in 76.2% and 66.7% of patients, respectively,
compared with 84.6% and 72.3% from the pooled analy-
sis. As in previous studies, mechanism-based irAEs
affecting the skin and gastrointestinal system were the
most common toxicities observed and irAEs were gener-
ally reversible using product-specific treatment guide-
lines [4].
Variations within an individual patient’sg e n o m eo r
somatic changes in the tumor DNA can affect disease
progression and management. An increased understand-
ing of how genetic variation can influence disease pro-
cesses may allow physicians to personalize medicine
through the design of individualized strategies for moni-
toring, prevention, and treatment that are the most
effective for a given patient. Determination of a patient’s
g e n e t i cp r o f i l em a yc o n t r i b u t et ot h ep r i m a r yg o a l so f
personalized medicine by guiding the selection of treat-
ments that maximize the chance for successful out-
comes while minimizing adverse events [38]. Interest in
personalized medicine is growing within the oncology
community as evidence accumulates showing that differ-
ential clinical responses to a number of anticancer drugs
can be associated with characteristics of an individual
patient.
Recent reports include examples of this from studies
of both melanoma and other cancers. Vemurafenib
(PLX4032) is a selective inhibitor of the oncogenic
V600E mutant BRAF kinase. In a melanoma study of 21
patients who received a sufficiently high dose of vemur-
afenib, 5 without the V600E BRAF mutation did not
respond to the drug; however, of 16 patients with the
mutation, 9 responded to vemurafenib and 7 did not
[18]. In a phase II study of imatinib for advanced mela-
noma, a substantial proportion of patients with tumors
characterized by mutation or amplification of KIT
responded to the drug whereas it had limited activity in
a nonselected population of melanoma patients [39].
Results of the CRYSTAL trial indicate that the clinical
activity of cetuximab against metastatic colorectal cancer
is enhanced in patients with wild-type KRAS compared
with individuals having KRAS mutations, none of whom
benefited from cetuximab treatment [40]. The identifica-
tion of predictive biomarkers for immunotherapies such
as ipilimumab will likely require interrogation of the
immune functional status of the patient in addition to
genomic analysis.
T h ep r e s e n c eo fT I L s ,i n d i c a t i n ga na n t i t u m o r
immune response, is a favorable prognostic indicator in
a number of cancers [41-45]; however, the prognostic
significance of TILs in melanoma remains unclear [46].
In this study, CA184-004, the clinical activity of ipilimu-
mab was positively associated with an increase in TILs
from baseline, suggesting that the infiltrating lympho-
cytes may have anti-tumor activity, and that changes in
the immune microenvironment of the tumor may slow
disease progression. There likely are other changes in
immune cell demographics, localization, and function
that are involved in melanoma progression. Peripheral
Table 8 Medium-resolution HLA-A genotyping: status of common alleles by clinical activity status: all response-
evaluable patients with medium-resolution HLA genotype data.
Allele* Clinical Activity Status n (%)
Allele Present Allele Absent Allele status unknown Total
02 Benefit 8 (72.7) 3 (27.3) 1 (8.3) 12 (17.9)
Non-Benefit 28 (65.1) 15 (34.9) 3 (6.5) 46 (68.7)
Unknown 3 (37.5) 5 (62.5) 1 (11.1) 9 (13.4)
24 Benefit 1 (10.0) 9 (90.0) 2 (16.7) 12 (17.9)
Non-Benefit 12 (28.6) 30 (71.4) 4 (8.7) 46 (68.7)
Unknown 2 (25.0) 6 (75.0) 1 (11.1) 9 (13.4)
03 Benefit 2 (20.0) 8 (80.0) 2 (16.7) 12 (17.9)
Non-Benefit 9 (21.4) 33 (78.6) 4 (8.7) 46 (68.7)
Unknown 2 (25.0) 6 (75.0) 1 (11.1) 9 (13.4)
01 Benefit 1 (16.7) 5 (83.3) 6 (50.0) 12 (17.9)
Non-Benefit 8 (20.5) 31 (79.5) 7 (15.2) 46 (68.7)
Unknown 2 (28.6) 5 (71.4) 2 (22.2) 9 (13.4)
11 Benefit 2 (20.0) 8 (80.0) 2 (16.7) 12 (17.9)
Non-Benefit 6 (14.3) 36 (85.7) 4 (8.7) 46 (68.7)
Unknown 1 (12.5) 7 (87.5) 1 (11.1) 9 (13.4)
*Only alleles present in at least 10% of all patients are shown.
Denominator for percents in columns “Allele Present” and “Allele Absent” is number of patients in row with known allele status.
Denominator for percents in column “Allele Status Unknown” is row total.
Denominator for percents in column “Total” is 67, the total number of patients in the data set.
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demonstrated prognostic value in a number of malig-
nancies [47-50]. Association between clinical activity of
ipilimumab and change from baseline in ALC was stu-
died in the current trial [24] and is being explored
further.
In the current study, higher protein levels of IDO and
FoxP3 at baseline were significantly positively associated
with clinical outcome and therefore may be predictive
of ipilimumab clinical activity. Increased expression of
IDO has been associated with an immunosuppressive
tumor microenvironment or a response to chronic
inflammation [51,52]. In melanoma, baseline expression
of IDO by tumors or infiltrates has been associated with
faster tumor growth, lower antitumor T-cell responses,
and poor prognosis [53]; however, recent data suggest
that IDO may induce apoptosis of melanoma tumor
cells [54]. Furthermore, the presence of IDO might be a
consequence of an active immune microenvironment
since IDO expression is induced by pro-inflammatory
cytokines such as IL-1, interferon-g and tumor necrosis
factor-a [55-57]. It is possible that IDO expression is
up-regulated in tumors from patients with an ongoing,
albeit suboptimal, antitumor immune response and that
these individuals may be more likely to respond to ipili-
mumab. Further investigation of the role of IDO in mel-
anoma and its value as a biomarker for ipilimumab is
warranted.
FoxP3 has been identified as a marker of natural and
adaptive/induced regulatory T cells (Tregs)[ 5 8 ] .P a t i e n t s
with cancer have higher levels of Tregs in peripheral
blood than healthy individuals [59], leading to a sup-
pression of T-cell immunity that has an immunopatho-
logic role in tumor growth [56] and influences
prognosis in many cancers [60-63]. Metabolic degrada-
tion of tryptophan by IDO promotes the conversion of
naïve T cells to Tregs [64,65]. Thus, intratumoral expres-
sion of IDO may have promoted the accumulation of
FoxP3
+ cells; however, recent findings suggest that
FoxP3 may not be specific for Tregs, but can also be
expressed by other activated T-cell populations [66].
Other reports suggest that the ratio of effector T cells
(Teffs)t oT regs, rather than changes in the absolute num-
ber of intratumoral Teffs or Tregs, may be a more specific
biomarker of effective antitumor immune responses eli-
cited by CTLA-4 blockade [67,68].
Results from CA184-004 are similar to those found
with tremelimumab, another anti-CTLA-4 antibody. In
a pilot study of 15 tumor biopsies from 7 tremelimu-
mab-treated patients, clinical response was associated
with increased tumor infiltration by CD8
+ TILs whereas
am o r ev a r i a b l ea s s o c i a t i o nw a sf o u n dw i t ht u m o ri n f i l -
tration of CD4
+ TILs [69]. The presence of FoxP3
+ reg-
ulatory T cells, indicative of an immunosuppressive
tumor microenvironment, was also variably associated
with positive response. No apparent association between
clinical response and intratumoral expression of IDO
was seen in that study.
In addition to FoxP3 and IDO, other proteins likely
are involved in creating an anti-tumor immune micro-
environment. Pharmacodynamic microarray data on
m R N Ad e r i v e df r o mt u m o rs a m p l e ss h o w e dt h a ti p i l i -
mumab led to altered gene expression in the tumor
microenvironment, significantly increasing expression of
immune-related genes, and significantly decreasing the
expression of genes linked to melanoma. This analysis
provides a list of candidate genes for further investiga-
tion to determine whether changes in gene expression
support anti-tumor activity and/or are associated with
clinical efficacy. Protein levels do not always correlate
with mRNA expression and so candidate genes of inter-
est should be confirmed by protein assays. Analyses of
the relationship between expression changes and clinical
efficacy are described in a separate manuscript that has
been submitted for publication. In a previous study of
ipilimumab in melanoma patients, associations between
SNPs in the CTLA-4 gene and objective response were
suggested [70]; such associations were not observed in
the current study. Consistent with a previous study
reporting that ipilimumab-treated patients with
advanced melanoma have similar survival outcomes
regardless of their HLA-A*0201 status [71], the current
study found no association between clinical activity and
the presence of the *0201 allele or any of the five most
common HLA-A alleles.
The associations of clinical activity with increased
TILs during treatment and with baseline expression of
IDO and FoxP3 suggest that an immune-active tumor
microenvironment might be necessary for a favorable
response to ipilimumab. The increased expression of
immune-related genes after treatment with ipilimumab
suggest additional genes to be tested for their involve-
ment in the creation of this immune-active tumor
microenvironment.
Conclusions
Baseline expression of immune-related tumor biomar-
kers and a post-treatment increase in TILs may be posi-
tively associated with ipilimumab clinical activity. These
preliminary results are hypothesis generating and sup-
port the need for larger prospective trials to confirm
these findings and further characterize other potential
biomarkers for ipilimumab.
Additional material
Additional file 1: Table S1. Specifications for antibodies used in IHC
analyses.
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Additional file 3: Table S3. Joint frequencies of clinical activity and
change from baseline of tumor biopsy H&E scores: TILs.
Additional file 4: Table S4. Joint frequencies of clinical activity and
pretreatment tumor biopsy IHC scores: FoxP3.
Additional file 5: Table S5. Joint frequencies of clinical activity and
pretreatment tumor biopsy IHC scores: FoxP3. Joint frequencies of clinical
activity and pretreatment tumor biopsy IHC scores: IDO.
Additional file 6: Figure S1. mRNA Expression in tumor biopsies: scatter
plot summarizing magnitude and significance of changes from baseline.
Additional file 7: Table S6. Model estimates for probe sets with time
effect q-value < 0.05 and expression level increased from baseline.
Additional file 8: Table S7. Model estimates for probe sets with time
effect q-value < 0.05 and expression level decreased from baseline.
Additional file 9: Table S8. Model estimates for probe sets with time
effect q-value < 0.05 and opposite direction of change from baseline.
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